Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration | Zendy

David W. Haas | Zendy; John Bartlett | Zendy; Janet W. Andersen | Zendy; Ian Sanne | Zendy; G. Wilkinson | Zendy; John E. Hinkle | Zendy; Franck Rousseau | Zendy; C.D. Ingram | Zendy; Audrey L. Shaw | Zendy; Michael M. Lederman | Zendy; Richard B. Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration

Author(s) -

David W. Haas,

John Bartlett,

Janet W. Andersen,

Ian Sanne,

G. Wilkinson,

John E. Hinkle,

Franck Rousseau,

C.D. Ingram,

Audrey L. Shaw,

Michael M. Lederman,

Richard B. Kim

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/507097

Subject(s) - nevirapine , medicine , pharmacogenetics , cyp3a , pharmacology , cyp2b6 , randomized controlled trial , reverse transcriptase inhibitor , clinical trial , oncology , human immunodeficiency virus (hiv) , virology , genotype , genetics , sida , gene , viral disease , biology , cyp3a4 , viral load , cytochrome p450 , antiretroviral therapy , metabolism

Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research